Samrat Pharmachem News

Samrat Pharmachem Board Meet on May 30 for FY26 Results

Samrat Pharmachem Limited has scheduled its board meeting for May 30, 2026, to consider and approve audited standalone financial results for FY26 under Indian Accounting Standards.

Samrat Pharmachem Q3 FY26 Loss Widens to Rs 45.95 Lakhs

Samrat Pharmachem Limited reported a net loss of Rs 45.95 lakhs for Q3 FY26 compared to a profit of Rs 278.48 lakhs in Q3 FY25. Revenue remained flat at Rs 6,382.71 lakhs versus Rs 6,366.53 lakhs year-on-year.

Samrat Pharmachem's Credit Rating Downgraded by Crisil to BB/Negative from BBB-/Stable

Crisil downgraded Samrat Pharmachem Limited's bank facilities rating to Crisil BB/Negative/Crisil A4+ from Crisil BBB-/Stable/Crisil A3, affecting Rs 30 crore of total bank loan facilities. The downgrade reflects deterioration in the company's business risk profile, led by decline in operating margin to negative 0.14% in H1 FY2026, despite maintaining strong capital structure with low debt reliance.

Samrat Pharmachem Reports Loss in Q2 FY26 Despite Revenue Growth

Samrat Pharmachem Limited posted a net loss of Rs 58.73 lakhs for Q2 ended September 30, 2025, despite revenue growth to Rs 7,887.03 lakhs from Rs 7,172.22 lakhs in the same quarter last year. The pharmaceutical chemicals manufacturer's half-year loss widened to Rs 81.62 lakhs compared to a profit of Rs 472.66 lakhs in the previous year, with earnings per share declining to negative Rs 2.64.